Background
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder characterized by a variety of organ system changes. Its name is derived from the characteristic changes that occur in the brain, called tubers. Over time, these tuberous growths become hard and sclerotic and may calcify. Until recently, most of the proliferations and tumors associated with the disease were thought to be hamartomas. Recent molecular biological analysis has revealed that these are clonal processes and true neoplastic growths. The TSC1 and TSC2 genes behave as tumor suppressor genes. If a somatic mutation of the second allele occurs, abnormal cell growth and differentiation occur.
The current diagnostic criteria divide the disease into diagnostic categories based upon the combination of clinical and histological findings.
Definite TSC:Either 2 major features or 1 major feature and 2 minor features
Possible TSC: Either 1 major feature or 2 or more minor features
Major Features Minor Features Facial angiofibromas or forehead plaque
Nontraumatic ungual or periungual fibroma
Hypomelanotic macules (more than 3)
Shagreen patch (connective tissue nevus)
Multiple renal nodular hamartomas
Cortical tuber*
Subependymal nodule
Subependymal giant cell astrocytoma
Cardiac rhabdomyoma, single or multiple
Lymphangiomyomatosis**
Renal angiomyolipoma**Multiple randomly distributed pits in dental enamel
Hamartomatous rectal polyps
Bone cysts
Cerebral white matter migration lines-may be diagnosed radiologically
Gingival fibromas
Nonrenal hamartomas
Retinal achromatic patch
Confetti skin lesions
Multiple renal cysts*When cerebral cortical dysplasia and cerebral white matter migration tracts occur together, they should be counted as 1 rather than 2 features of TSC
**When both lymphangioleiomyomatosis and renal angiomyolipomas are present, other features of TSC should be present before a definitive diagnosis is assigned.
OUTLINE
EPIDEMIOLOGY CHARACTERIZATION SYNONYMS Bourneville disease INCIDENCE 1/8000
PATHOGENESIS-TUBEROUS SCLEROSIS (TSC)
CHARACTERIZATION TSC1 TSC2 Chromosome location 9q34 16p13 Mutational spectrum, % Large deletion and rearrangement2 17 Small deletion and insertion56 33 Nonsense37 20 Splice5 6 Misense0 23 Number of exons 139 250 mRNA size in KB 8.6 5.5 Protein product length 1164 1784 Protein product name Hamartin Tuberin Protein function Associates physically with tuberin Negative growth regulator
Putatative GTPase activating protein for rap1 and rab5
ADDITIONAL PATHOGENETIC MECHANISMS CHARACTERIZATION GENERAL Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms
Jack L. Arbiser, MD, PhD
Daniel Brat, MD, PhD
Steve Hunter, MD, etal.
Atlanta, Georgia, New York, New York, Philadelphia, Pennsylvania, and Tucson, Arizona
J Am Acad Dermatol 2002;46:376-80 Abstract quote
Background: Tuberous sclerosis is an autosomal dominant condition characterized by the development of benign neoplasms of the brain, kidney, and skin. Progressive growth and malignant transformation of brain and kidney lesions constitute the major cause of morbidity and mortality in adults with tuberous sclerosis. In addition, growth of skin lesions may be disfiguring to patients.
Objective: The purpose of this study was to determine whether benign tumors in patients with tuberous sclerosis are angiogenic.
Methods: Brain, kidney, and skin tumors from patients with tuberous sclerosis were stained with CD31, a specific marker of vascular endothelium. In addition, we used Northern blot analysis to demonstrate that renal angiomyolipoma cells express the potent angiogenesis stimulator vascular endothelial growth factor (VEGF).
Results: Brain, kidney, and skin neoplasms from patients with tuberous sclerosis are highly angiogenic. Renal angiomyolipoma cells produce the potent angiogenic factor VEGF.
Conclusion: Benign neoplasms of patients with tuberous sclerosis are highly vascular. Our results provide a rationale for antiangiogenic therapy in the treatment and prevention of tuberous sclerosis-associated neoplasms.
TUBERIN Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis
Phuong-Anh Nguyen-Vu1, Ingrid Fackler1, Adelheid Rust2, Jeffrey E. DeClue3, Christian A. Sander1, Matthias Volkenandt1, Michael Flaig1, Raymond S. Yeung4 and Ralf Wienecke1 1
Department of Dermatology, Ludwig-Maximilians-University Munich, Munich, Germany, 2 Department of Dermatology, Mayo Clinic and Foundation, Rochester, Minnesota, USA, 3 National Cancer Institute, Laboratory of Cellular Oncology, Bethesda, Maryland, USA, 4 Department of Surgery & Division of Medical Genetics, University of Washington, Seattle, Washington, USA
Journal of Cutaneous Pathology 2001;28 (9), 470-475
Background: Tuberous sclerosis complex (TSC) is an autosomal dominantly inherited disorder associated with an alteration of the TSC2 tumor suppressor gene which encodes for the protein product tuberin. The disease is characterized by the development of hamartomas, e.g. cutaneous angiofibromas which consist of vascular cells, interstitial cells, and normal components of the skin. The Eker rat model, an animal model of inherited cancer, has been shown to carry a mutation of TSC2.
Methods: Immunohistochemical analyses of human angiofibromas were performed using antibodies directed against tuberin and angiogenic growth factors. Proliferation of human dermal microvascular endothelial cells (HDMEC) was determined after incubation with the supernatants of TSC2 (+/+) and TSC2 (-/-) rat embryonic fibroblasts (REF) that were derived from the Eker strain.
Results: Loss of the expression of tuberin was observed in the interstitial cells of 13 of 39 angiofibromas. The expression of tuberin was retained in the vascular cells. In all analyzed angiofibromas, the angiogenic factors bFGF, PD-ECGF, VEGF and angiogenin were detected in the interstitial cells and/or vascular cells. Expression of PDGF-B and TGF-b1 was weak. Tissue culture supernatants from TSC2 (-/-) REF stimulated the growth of HDMEC significantly more than supernatants from TSC2 (+/+) REF.
Conclusion: A functional loss of tuberin may stimulate vascular growth.
Reduction of expression of tuberin, the tuberous-sclerosis-complex-gene-2 product in tuberous sclerosis complex associated connective tissue nevi and sporadic squamous and basal cell carcinomas.Wienecke R, Klemm E, Karparti S, Swanson NA, Green AJ, DeClue JE.
Department of Dermatology and Allergology, Ludwig-Maximilians-University Munich, Munich, Germany, National Institutes of Health, National Cancer Institute, Laboratory of Cellular Oncology, Bethesda, Maryland, USA, Department of Dermatology, Semmelweis University, Budapest, Hungary, Oregon Health Sciences University, Department of Dermatology, Portland, Oregon, USA, Department of Medical Genetics and Conway Institute, University College Dublin, Ireland
J Cutan Pathol 2002 May;29(5):287-290 Abstract quote Background: Patients affected with tuberous sclerosis complex (TSC) are prone to the development of multiple benign tumors of the skin and other organs. Tuberin, the protein product of the tuberous-sclerosis-complex-2 tumor suppressor gene (TSC2) has been shown to inhibit cell proliferation. In TSC associated kidney tumors and sporadic brain tumors the loss/reduction of tuberin has been shown.
Methods: Specimens of nine squamous cell carcinomas (SCC) and five basal cell carcinomas (BCC) from patients without TSC and six biopsies of connective tissue nevi (CTN) of patients with TSC were obtained. Specimens were analyzed by immunoblotting for the expression of tuberin. Results: Absent or reduced levels of tuberin were detected in the dermal parts of three of six shagreen patches, two of five BCC, and four of nine SCC.
Conclusions: In tumors/hamartomas of patients with TSC the complete loss of TSC2 and tuberin is a mechanism which could be shown for CTN, thereby excluding the possibility of haploinsufficiency of TSC2. In a substantial number of cutaneous BCC and SCC the loss or downregulation of tuberin seems to be epigenetic, as alterations of TSC2 are not known in these tumors. The absence or reduction of tuberin might contribute to their proliferation.
LABORATORY/RADIOLOGIC/OTHER TESTS CHARACTERIZATION Radiographs CT radiologic study Characteristic subependymal calcifications
Arch Neurol 2000;57:662-665.
Henry JB. Clinical Diagnosis and Management by Laboratory Methods. Twentieth Edition. WB Saunders. 2001.
Rosai J. Ackerman's Surgical Pathology. Eight Edition. Mosby 1996.
Sternberg S. Diagnostic Surgical Pathology. Third Edition. Lipincott Williams and Wilkins 1999.
Robbins Pathologic Basis of Disease. Sixth Edition. WB Saunders 1999.
DeMay RM. The Art and Science of Cytopathology. Volume 1 and 2. ASCP Press. 1996.
Weedon D. Weedon's Skin Pathology Second Edition. Churchill Livingstone. 2002
Fitzpatrick's Dermatology in General Medicine. 5th Edition. McGraw-Hill. 1999.
Weiss SW and Goldblum JR. Enzinger and Weiss's Soft Tissue Tumors. Fourth Edition. Mosby 2001.
Basic Principles of Disease
Learn the basic disease classifications of cancers, infections, and inflammation
Commonly Used Terms
This is a glossary of terms often found in a pathology report.Diagnostic Process
Learn how a pathologist makes a diagnosis using a microscopeSurgical Pathology Report
Examine an actual biopsy report to understand what each section meansSpecial Stains
Understand the tools the pathologist utilizes to aid in the diagnosisHow Accurate is My Report?
Pathologists actively oversee every area of the laboratory to ensure your report is accurate
Last Updated 4/17/2003
Send mail to The Doctor's Doctor with questions or comments about this web site.
Copyright © 2004 The Doctor's Doctor